Precigen, Inc.PGEN

Precigen spent $43.8 million more in operating cash than it generated in the first quarter of 2026, despite booking $23.3 million in revenue, according to the company’s own 10-Q filed on 31 March 2026. The filing also shows cash and equivalents at just $7.5 million, liabilities of $118.4 million, and shareholders’ equity of $20.2 million, leaving the balance sheet more stretched than a gene-editing primer being pulled in opposite directions. (source: SEC EDGAR 10-Q for PRECIGEN, Inc. (CIK 0001356090), period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1356090/000095010326009979/xslF345X06/ownership.xml)

Precigen bills itself as a ‘commercial-stage biopharmaceutical company’ focused on delivering precision medicines for difficult-to-treat diseases, and its website and press releases trumpet UltraCAR-T-a platform said to compress autologous CAR-T manufacturing to a single day. Yet the same 10-Q shows net cash used in operating activities of $43.8 million, a $4.9 million inventory build, and heavy R&D spend of $5.6 million, while paying out only $258,000 in capital expenditure. The platform’s promise is real; the cash reality is tighter than the squeeze on a transposon plasmid. (source: Precigen: Advancing Medicine with Precision, https://precigen.com; 10-Q for period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1356090/000095010326009979/xslF345X06/ownership.xml)

Precigen’s latest quarterly filing for the three months ended 31 March 2026 shows revenue of $23.3 million, a net loss of $7.9 million, and operating loss of $6.0 million. Diluted EPS came in at negative $0.02 on 354.3 million shares, while the company still managed to burn $43.8 million in operating cash and increase inventories by $4.9 million. Short-term investments stood at $48.8 million, a cushion that still only covers six weeks of operating outflows at current burn rates. (source: SEC EDGAR 10-Q for PRECIGEN, Inc. (CIK 0001356090), period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1356090/000095010326009979/xslF345X06/ownership.xml)

For a closer look at the company’s pipeline and product claims, Precigen’s official science and pipeline pages outline its focus on immuno-oncology, autoimmune disorders, and infectious diseases, while highlighting UltraCAR-T’s one-day manufacturing advantage. The evidence is promotional rather than financial proof of scale, but it does ground what the company is selling versus what the balance sheet can still support. (source: Science - Precigen, https://precigen.com/science/; Pipeline - Precigen, https://precigen.com/pipeline/)

Shareholders approved a charter amendment at the 2026 annual meeting on 18 June, but the filing offers no quantitative rationale-just the procedural tick that keeps the lights on in the management desks. The company’s May 2026 press release boasted ‘strong momentum’ with $21.6 million in net product revenue for Q1 2026, yet the 10-Q’s operating cash burn and inventory buildup suggest momentum hasn’t yet translated into liquidity. The tension between narrative and numbers is the story, not the spin. (source: Precigen press release dated 13 May 2026, https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_ex9901.htm; SEC EDGAR 8-K filed 2026-06-24, https://www.sec.gov/Archives/edgar/data/1356090/000095010326009441/dp248898_8k.htm)

What remains unproven is whether Precigen’s precision therapies can scale revenue fast enough to offset the cash burn. The company’s cash outflows, inventory build, and heavy R&D are all disclosed; what’s missing is evidence of accelerating commercial uptake that would flip the burn into build. Until the operating cash flow line turns positive, the platform’s promise is a slide-deck story, not a balance-sheet reality. (source: SEC EDGAR 10-Q and 8-K as above)